Metastatic Clear Cell Renal Cell Carcinoma research hub
4 indexed studies · 3 currently recruiting
- recruitingPHASE3
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
This study is looking at a new drug, casdatifan, combined with an existing one, cabozantinib, for advanced clear cell kidney cancer. It compares this combination to cabozantinib with a dummy drug (placebo) to see if it stops cancer growth for longer in patients who've already had immunotherapy.
United States · Australia · Canada - recruitingPHASE2
Radiopharmaceutical Treatment of Advanced Kidney Cancer
This study explores a new treatment, 177Lu-PSMA-617, for advanced kidney cancer that has spread. It's for people whose cancer hasn't responded to other treatments. We're checking if it helps shrink tumours and is safe, similar to how it's used for prostate cancer.
France - recruitingEARLY_PHASE1
[18F] PSMA-1007 PET/CT in Metastatic Clear Cell Renal Cell Carcinoma
This study uses a special scan called a PET/CT with a medicine called [18F] PSMA-1007 to find kidney cancer that has spread. It aims to see if this new scan can find cancer spots that regular scans miss, helping doctors plan the best treatment.
Canada - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-label, Randomized, Noninferiority Trial of the Subcutaneous Formulation of Nivolumab Versus Intravenous Nivolumab in Participants With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Who Had Received Prior Systemic Therapy
This study compares two ways of giving a medicine called Nivolumab for advanced kidney cancer. One way is an injection under the skin, and the other is a drip into a vein. Doctors want to see if the injection works just as well and is safe for patients.
Italy · Spain · Finland